Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
- Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
...
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
- Associated Therapies
- -
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyBiological: BlinatumomabDrug: Calaspargase PegolDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: DaunorubicinDrug: DoxorubicinProcedure: EchocardiographyDrug: LeucovorinDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PegaspargaseDrug: PrednisoloneDrug: PrednisoneDrug: VincristineRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 680
- Registration Number
- NCT06124157
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
- Conditions
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 180
- Registration Number
- NCT05959720
- Locations
- 🇧🇷
Instituto do Cancer do Estado de Sao Paulo, São Paulo, SP, Brazil
VA vs DA for Newly Diagnosed Hig-risk AML
- Conditions
- Interventions
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2024-04-09
- Target Recruit Count
- 116
- Registration Number
- NCT05939180
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
🇨🇳Ethical Committee of the First Affliated Hospital of Soochow University, Suzhou, Jiangsu, China
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT05886049
- Locations
- 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
Optimum Induction Therapy of Low-risk APL
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 74
- Registration Number
- NCT05832320
- Locations
- 🇨🇳
Peking University Institute of Hematology, Beijing, Beijing, China
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT05735184
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸USC University of Southern California / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA - Bowyer Oncology Center, Los Angeles, California, United States
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Shanxi Bethune Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05726110
- Locations
- 🇨🇳
Tao Wang, Taiyuan, Shanxi, China
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2023-03-03
- Target Recruit Count
- 100
- Registration Number
- NCT05660473
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Ioannis Mantzaris
- Target Recruit Count
- 99
- Registration Number
- NCT05342584
- Locations
- 🇺🇸
Montefiore Einstein Cancer Center, Bronx, New York, United States
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT04817241
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.